Tag
This study investigates how dose reductions and discontinuations of antifibrotic therapies influence disease progression in idiopathic pulmonary fibrosis (IPF), revealing significant challenges in drug tolerability and the need for improved
This study investigates the efficacy of topical and systemic pirfenidone in reducing glottic stenosis induced by bleomycin in rats, demonstrating both routes reduce macroscopic stenosis, with systemic administration showing significant anti
A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.
The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.
